UPDATE 2-U.S. FDA declines to approve Sarepta's second Duchenne treatment

Sarepta Therapeutics Inc said on Monday the U.S. Food and Drug Administration declined to approve its newest treatment for Duchenne muscular dystrophy (DMD), citing safety concerns including the risk of infection and kidney toxicity.

from Reuters: Company News https://ift.tt/2P4XSdi